Page 150 - 80 guidelines for the treatment of malaria_opt

nd
nd
Guidelines for the treatment of malaria – 2
Guidelines for the treatment of malaria – 2 edition edition
importance CRITICAL IMPORTANT IMPORTANT IMPORTANT IMPORTANT

Quality MODERATE MODERATE VERY LOW VERY LOW
–
80 fewer per 1000 (from 52 fewer 114 fewer per 1000 (from 81 fewer 17 fewer per 1000 (from 40 fewer Not estimable

Absolute to 95 fewer) to 136 fewer) to 43 more) –

effect Relative risk (95% CI) RR 0.3 (0.17–0.54) RR 0.37 (0.25–0.55) RR 0.7 (0.27–1.79) Not estimable –
Is DHA+PPQ superior to AQ+SP for treating uncomplicated P. falciparum malaria in Africa?

summary of findings no. of patients AQ + SP DHA + PPQ 45/394 14/408 (11.4%) (3.4%) 77/426 28/422 (18.1%) (6.6%) 10/183 7/184 (5.5%) (3.8%) 0/187 0/187 (0%) (0%) – –

considerations

Other None None None None –

Imprecision No serious imprecision 8 No serious imprecision 8 Very serious 10 Very serious 12 –

Indirectness Serious 6,7 Serious 6,7 Serious 6,11 Serious 11 –

Inconsistency No serious inconsistency 5 No serious inconsistency 5 Not applicable Not applicable

Limitations No serious limitations 3,4 EFFICACy: total failure (P . falciparum) day 28 PCR unadjusted 1 No serious limitations 3 TRANSMISSION POTENTIAL: gametocyte development (in those negative at baseline) No serious limitations 9 No serious limitations 9 –

GRADE Table A7.1.1 Quality assessment Design EFFICACy: total failure (P . falciparum) day 28 PCR adjusted 1 Randomized trial 2 Randomized trial 2 Randomized trial HARMS: serious adverse events (including deaths) Randomized trial HARMS: early vomiting – not reported 13 -– –

136 No. of studies 2 2 1 1 0